Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
phenylephrine FDA

COVID remnants still show up on PET/CT scans years after infection

That’s according to new PET imaging that shows the presence of activated T cells in the brain, spinal cord, gut and lung tissues of individuals who have recovered from COVID.

Marsha Blackburn

Bipartisan senators urge CMS to bolster access to nuclear imaging in outpatient settings

Lawmakers led by Sen. Marsha Blackburn, R-Tenn., made their plea in a June letter to the head of the agency. 

brain money alzheimer dementia

Implications for radiology following the FDA’s approval of new Alzheimer’s treatment from Eli Lilly

Providers are required to obtain a recent baseline brain MRI prior to initiating treatment and individuals also must undergo scans prior to the second, third, fourth and seventh infusions. 
 

lantheus acquires rights from life molecular imaging

Lantheus lands rights to budding radiopharmaceuticals for initial outlay of $35M

One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.

Thumbnail

Frequent sleep disruptions may increase amyloid deposits down the road

Daily sleep disruptions could increase the risk of developing Alzheimer’s disease in the future, new research suggests. 

Hearing aids help slow brain aging in individuals with mild cognitive impairment

Hearing aids help stall brain aging, new imaging study shows

For people with auditory impairment, hearing aid use could slow metabolic decline in regions of the brain associated with cognitive function.

Telix Pharmaceuticals

PET imaging-agent developer Telix seeks to raise $200M through initial public offering

The Australian radiopharma firm's financial maneuver comes amid its roll out of the first targeted positron emission tomography agent for kidney cancer. 

Imaging advocacy group finds solution to ‘significant obstacle’ fueling shortages of PET/CT professionals

Demand is growing for the modality, but provider groups, particularly those in private practice, have struggled to meet state regulatory requirements. 

Displaying 57 - 64 of 329
Design by Adaptive Theme